Alerts

We have made a Serious Scarcity Substitution Instrument (SSSI) that starts on 22 December 2025 and ends on 28 April 2026. The SSSI allows a pharmacist to dispense an equivalent quantity of clonidine 100 mcg tablets, if appropriate, without a new prescription

Pharmaceutical companies Novo Nordisk and Eli Lilly are discontinuing some of their insulin products.

Pharmacists can substitute 10 mg simvastatin tablets during the shortage of the 5 mg tablets.

Pharmacists can substitute whichever brand and strength of nicorandil is available during the shortage.

We have extended the Therapeutic Goods (Serious Scarcity and Substitutable Medicine) (Labetalol) Instrument 2025 (SSSI) to 31 December 2025.

Pharmacists can dispense 200 mg tablets during the shortage.

Concerta modified-release tablets will remain in shortage at various times until the end of 2026

All strengths of the Mounjaro vial presentation are discontinued but the Mounjaro KwikPen is available in the same strengths.

We have approved overseas-registered substitutes for Pegasys 135 micrograms/0.5 mL and 180 micrograms/0.5 mL pre-filled syringes.

Various brands of metformin hydrochloride 1000 mg immediate-release tablets are in shortage.

Ritalin and Artige immediate-release tablets are now also in shortage, and a shortage of Ritalin LA capsules is anticipated.

Takeda Pharmaceuticals Australia has issued a product alert for Vyvanse capsules due to minor packaging errors. The medication is safe to use as prescribed.

More prominent warnings are being added to the Product Information and Consumer Medicine Information for all oral and injectable (systemic) fluoroquinolones to strengthen existing warnings about serious side effects.

Possible risk of learning, communication and behaviour problems in children born to men taking this medicine.

Extra safety information is being added to all montelukast products to highlight the existing warnings about serious behaviour and mood-related changes

Pharmacists can use a Serious Scarcity Substitution Instrument (SSSI) to dispense Protaphane Penfill human insulin in the place of a Protaphane InnoLet cartridge.

Gold Max Blue capsules pose a serious risk to your health and should not be taken.

Dynamint X tablets pose a serious risk to your health and should not be taken.

Pharmacists may dispense alternative brands or strengths without a new prescription.

The oral antihistamine promethazine hydrochloride, sold as Phenergan and other generic brands, should not be given to children under 6 years of age.

African Vigorous Max Strength poses a serious risk to your health and should not be taken.

We have tested a further 6 imported, unregistered ivermectin products and found they are counterfeit under the Therapeutic Goods Act 1989.

Ziyinzhuangyang tablets pose a serious risk to your health and should not be taken.

The TGA has received reports of serious adverse events in infants and children who have been given compounded wind and colic preparations containing Atropa belladonna (belladonna).

Read our safety advisory about this ingredient's potential to cause severe allergic reactions including anaphylaxis.